ClinicalTrials.gg
Not yet recruitingNCT05937451PRIMEUpdated Jul 28, 2023

Prediction and Management of Acute Kidney Injury With Explainable Artificial Intelligence

An interventional study of PRIME solution in Acute Kidney Injury, sponsored by Seoul National University Hospital. Not yet recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2023-07-28.

Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,438
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Acute Kidney Injury by Seoul National University Hospital — 3 open to participants now, 3 under way, none of them phase 3. Acute Kidney Injury · Seoul National University Hospital.

Planned enrollment
Largest of 11
1,438 · median 190
Started
2023
the only one that year
No phase
9 of 18
2 open now
Registered
15th of 18
by date

Among the 18 studies in Acute Kidney Injury by Seoul National University Hospital, this one has the largest planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2023, is one of 9 with no phase, and was the 15th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

3 of the 18 studies in Acute Kidney Injury by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Acute Kidney Injury by Seoul National University Hospital, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the occurrence of acute kidney injury (AKI) in inpatients when information from the 'PRIME solution' (AKI prediction program utilizing artificial intelligence) is provided. The main questions it aims to answer are: •[When Artificial intelligence (AI) provides information regarding AKI occurrence prediction within 48 hours, what would change in the physician's behavior?] •[If provided with AI information, what would be the incidence of AKI, severe AKI (stage 2 or 3), kidney replacement therapy, and changes in mortality during hospitalization?] In the case of the intervention group that receives AI information, autonomous treatment is conducted by referring to AI prediction information. Researchers will compare it with a usual-care group that does not receive AI prediction results.

Read the detailed description

The investigators designed a prospective, investigator-initiated, single-center, single-blinded, randomized controlled study with two experimental groups. A total of 1438 participants with hospitalized patients will be enrolled and randomized into two groups; intervention or usual-care groups. The investigators will apply an AKI prediction model based on the patient's demographic. The investigators will collect data on vital signs, laboratory test results, medication history, and surgical records. The investigators provide information on whether AKI develops within 48 hours and the top 10 explanatory factors for predicting AKI to the physician. The intervention group receives the prediction results daily until the patient is discharged or up to 7 days after admission. The usual-care group does not receive analysis results.

03

Conditions studied

  • Acute Kidney Injury

Browse trials for

Keywords

  • Acute kidney injury
  • Artificial intelligence
  • Explainable AI
  • Prediction
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inpatients aged > 18 years
  • Admitted to the Department of Nephrology, Geriatrics, Urology, Surgery, and Orthopedics
  • written consent

Exclusion criteria

Exclusion Criteria:

  • Patients with a scheduled hospital stay of 2 days or less
  • Patients who have been hospitalized for more than 8 days since the date of hospitalization
  • Patients scheduled to be discharged the next day
  • Patients with last measured serum creatinine greater than 4.0 mg/dL or less than Estimated Glomerular Filtration Fate Chronic Kidney Disease Epidemiology Collaboration (-CKD-EPI) 15 ml/min/1.73 m2
  • Patients undergoing dialysis (Hemodialysis, peritoneal dialysis) due to end-stage renal disease
  • Declined to participate
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
1,438 participants (estimated)

Study arms

  • Active comparator
    Intervention group

    The intervention group receives the prediction results daily until the patient is discharged or up to 7 days after admission.

    Other: PRIME solution

  • No intervention
    Usual care group

    The usual-care group does not receive analysis results. The user-care group continues the existing treatment.

Interventions

  • OtherPRIME solution

    The investigators will apply an AKI prediction model (PRIME solution) based on the patient's demographic. The investigators will collect data on vital signs, laboratory test results, medication history, and surgical records. The investigators provide information on whether AKI develops within 48 hours and the top 10 explanatory factors for predicting AKI to the physician.

06

What researchers measure

Primary outcomes

  1. physician's behavior change

    Physician's pattern of care changed after receiving AI prediction information The primary category of outcomes was the change in clinicians' behavior, including clinicians' medical treatment patterns, instances of overlooked AKI, and clinicians' consultation patterns. Medical treatment patterns of clinicians were classified into the following 5 categories: Patient assessment, Review of medication, Imaging workup, Monitoring hemodynamic stability, Evaluate furthermore. Overlooked AKI was defined as the absence of a follow-up Scr measurement within 2 weeks after AKI. Consultation to the nephrology division was classified into the following 3 outcomes: no consultation, early consultation, and late consultation. Early consultation was defined as consultation within 3 days from the AKI prediction. Consults issued more than 3 days after the AKI prediction were considered late consultations.

    Time frame: From the date of radomization until the patient is discharged or date of death from any cause, whichever came first, assessed up to 8 days after admission

Secondary outcomes

  1. incidence of AKI

    AKI is defined as any of the following (NotGraded): * Increase in SCr by ≥ 0.3mg/dl (≥26.5umol/l) within 48 hours;or * Increase in SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7days; or * Urine volume \< 0.5ml/kg/h for 6hours.

    Time frame: From the date of randomization until the patient is discharged or date of death from any cause, whichever came first, assessed up to 8 days after admission

  2. severe AKI (stage 2 or 3)

    stage 2: Serum creatinine (SCr) 2.0-2.9 times baseline or Urine output \< 0.5ml/kg/h for ≥12hours stage 3: Serum creatinine 3.0 times baseline or increase in serum creatinine to ≥ 4.0 mg/dl or initiation of renal replacement therapy or Urine output \< 0.3ml/kg/h for ≥24hours or Anuria for ≥ 12 hours

    Time frame: From the date of randomization until the patient is discharged or date of death from any cause, whichever came first, assessed up to 8 days after admission

  3. renal replacement therapy

    Patients who underwent renal replacement therapy

    Time frame: From the date of randomization until the patient is discharged or date of death from any cause, whichever came first, assessed up to 8 days after admission

  4. death

    patient who died during hospitalization

    Time frame: From the date of randomization until the patient is discharged or date of death from any cause, whichever came first, assessed up to 8 days after admission

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2023; primary completion for Dec 2024, 15 months later.

Of 251 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 15 months is below that.

Counting every sponsor, half of 269 studies reached it within 26 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2023
First posted
Jul 10, 2023
StartEst.
Sep 1, 2023
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2025
Last update
Jul 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05937451
Responsible party
Sejoong Kim (Associated professor, Seoul National University Hospital) — Principal investigator
First posted
Jul 10, 2023
Start date
Sep 1, 2023 (estimated)
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jul 28, 2023

Study contacts

Sejoong Kim, MD, PhD
Contact
sejoong2@snu.ac.kr
+821094964899
Giae Yun, MD
Contact
giaeyun0106@gmail.com
+821063268313
Sejoong Kim, MD, PhD
study chair · Seoul National University Bundang Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion